- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05934929
Contribution of Residual Tumour DNA Testing on the Surgical Bed (MARGINS)
Contribution of Residual Tumour DNA Testing on the Surgical Bed of Squamous Cell Carcinomas of the Oral Cavity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Squamous cell carcinomas of the oral cavity have a poor prognosis. The 5-year loco-regional recurrence rate is 45%. Surgery remains the standard treatment. The presence of invasive or insufficient surgical margins is an important histopronostic factor.
Current tools for intraoperative detection of insufficient margins have a very low sensitivity of around 10%. The aim here is to develop a more sensitive tool by looking for the presence of residual tumour DNA in the entire operating bed after squamous cell carcinoma excision
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Doriane Richard, PhD
- Phone Number: +33232082985
- Email: doriane.richard@chb.unicancer.fr
Study Contact Backup
- Name: Lise-Marie Roussel, MD
- Phone Number: +33232082985
- Email: lise-marie.roussel@chb.unicancer.fr
Study Locations
-
-
-
Rouen, France, 76038
- Centre Henri Becquerel
-
Contact:
- Lise-Marie Roussel, MD
- Phone Number: +33232082985
- Email: lise-marie.roussel@chb.unicancer.fr
-
Principal Investigator:
- Lise-Marie Roussel, Md
-
Rouen, France, 76000
- CHU Rouen
-
Contact:
- Sophie Deneuve, Md
- Email: sophie.deneuve@chu-rouen.fr
-
Principal Investigator:
- Sophie Deneuve, Md
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed informed consent
- Patient with T1 to T4 squamous cell carcinoma of the oral cavity, regardless of lymph node status (all N) M0, operable
- 18 years of age or older
- Member or beneficiary of a social security scheme.
Exclusion Criteria:
- Absence of signed informed consent
- Patient of protected age
- Psychosocial problems
- Not affiliated to or benefiting from a social security scheme
- Previous cervical irradiation
- Pregnant or breast-feeding women
- Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographical problems, etc.).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: circulating tumor DNA detection on operating bed
biological assessment on operating bed to detect residual circulating tumor DNA
|
biological assessment on operating bed to detect residual circulating tumor DNA
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Residual tumro DNA on operating bed
Time Frame: during the surgery
|
Proportion of patients with residual tumour DNA on the operating bed according to the presence or absence of adverse histological factors
|
during the surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival without locoregional recurrence rate
Time Frame: 24 months
|
Proportion of patients with circulating tumour DNA and in the cervical lymphatic drainage fluid or circulating blood according to the presence or absence of residual tumour DNA on the operating bed
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lise-Marie Roussel, MD, Centre Henri Becquerel
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHB23.01
- 2023-A00567-38 (Other Identifier: ANSM)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Squamous Cell Carcinoma of the Oral Cavity
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnRecurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Verrucous Carcinoma of the Oral Cavity | Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage I Squamous Cell Carcinoma of the Oropharynx | Stage I Verrucous... and other conditionsUnited States
-
Wake Forest University Health SciencesTerminatedStage I Adenoid Cystic Carcinoma of the Oral Cavity | Stage I Mucoepidermoid Carcinoma of the Oral Cavity | Stage I Squamous Cell Carcinoma of the Hypopharynx | Stage I Squamous Cell Carcinoma of the Larynx | Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage I Verrucous Carcinoma... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedTongue Cancer | Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage I Squamous Cell Carcinoma of the Oropharynx | Stage I Verrucous Carcinoma of the Oral Cavity | Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage II Squamous Cell Carcinoma of the Oropharynx | Stage... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingTongue Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Verrucous Carcinoma of the Larynx | Recurrent Verrucous Carcinoma of the Oral Cavity | Recurrent Adenoid... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)TerminatedRecurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Verrucous Carcinoma of the Larynx | Recurrent Verrucous Carcinoma... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedTongue Cancer | Salivary Gland Squamous Cell Carcinoma | Stage I Salivary Gland Cancer | Stage I Squamous Cell Carcinoma of the Hypopharynx | Stage I Squamous Cell Carcinoma of the Larynx | Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage I Squamous Cell Carcinoma of the Nasopharynx and other conditionsUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyWithdrawnTongue Cancer | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Verrucous Carcinoma of the Oral Cavity | Stage IVA Verrucous Carcinoma of the Oral Cavity | Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage IVB Verrucous Carcinoma of the Oral Cavity | Stage IVA Squamous Cell Carcinoma of the Lip and Oral CavityUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMucositis | Tongue Cancer | Oral Complications | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Verrucous Carcinoma of the Larynx | Recurrent... and other conditionsUnited States
-
Mitchell MachtayNot yet recruitingSquamous Cell Carcinoma of the Oral Cavity or Oropharynx
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnSquamous Cell Carcinoma of the Skin | Recurrent Skin Cancer | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage IVA Squamous Cell Carcinoma of the...United States
Clinical Trials on Circulating tumor DNA detection
-
Second Xiangya Hospital of Central South UniversityThe First Affiliated Hospital of Nanchang University; Xiangya Hospital of Central... and other collaboratorsRecruitingLung Cancer, Non-small Cell | Circulating Tumor DNA | EGFR Gene Mutation | EGFR-TKI Resistant Mutation | Primary ResistanceChina
-
Zhujiang HospitalNot yet recruitingRecurrence | Hepatocellular Carcinoma | Surgery | Circulating Tumor CellChina
-
Christer EricssonKarolinska Institutet; iCellate MedicalUnknownCancer | Neoplasms, Unknown PrimarySweden
-
Centre Henri BecquerelNot yet recruitingPeripheral T Cell LymphomaFrance
-
Zhujiang HospitalRecruitingHepatocellular Carcinoma ResectableChina
-
Rigshospitalet, DenmarkRecruitingGastric Cancer | Esophageal CancerDenmark
-
Helsinki University Central HospitalInstitute for Molecular MedicineUnknown
-
Fudan UniversityRecruiting
-
University Medical Center Ho Chi Minh City (UMC)RecruitingGastric Cancer | Circulating Tumor DNA (ctDNA)Vietnam
-
British Columbia Cancer AgencyUniversity of British Columbia; University of Utah; Pathway Genomics; Boreal GenomicsCompleted